Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location | |
|---|---|---|---|---|
|
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors |
Polycythemia Vera | Phase4 | Germany | NCT05853458 |
|
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis |
Scleroderma, Diffuse | Phase2 |
Australia France Germany Israel Italy Japan Netherlands Singapore Spain Switzerland Taiwan United States View All
|
NCT06655896 |
|
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG. |
Generalized Myasthenia Gravis | Phase3 |
China Greece Israel Italy Japan Poland Portugal Spain United Kingdom United States View All
|
NCT06517758 |
|
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V |
Lupus Nephritis | Phase2 |
Argentina Brazil China Colombia France Germany Hong Kong Hungary India Israel Malaysia Mexico Philippines Portugal Puerto Rico Singapore Spain Turkey (Türkiye) United Kingdom United States View All
|
NCT05268289 |
|
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors |
Solid Tumor | Phase1, Phase2 |
Australia Canada United States |
NCT04939610 |
|
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. |
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers | Phase1 |
Belgium China France Germany Israel Italy Japan Norway Singapore South Korea Spain Sweden Taiwan United Kingdom United States View All
|
NCT05838768 |
|
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). |
Systemic Lupus Erythematosus | Phase3 |
Argentina Australia Brazil Bulgaria Canada China Colombia Czechia France Germany Guatemala Hungary India Israel Italy Japan Malaysia Mexico Poland Portugal Romania South Korea Spain Taiwan Thailand United States View All
|
NCT06133972 |
|
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France |
Chronic Myeloid Leukemia | France | NCT06092879 | |
|
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer |
Breast Cancer | Phase1 |
China France Germany Poland Portugal Spain United States View All
|
NCT05870579 |
|
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS |
Atypical Hemolytic Uremic Syndrome | Phase3 |
Brazil China Czechia India View All
|
NCT05795140 |